指南与共识消化、代谢与肾脏急症重症综合管理与镇静镇痛

接受感染病药师建议的获益:多医院系统5年结局研究

Benefits of Accepting Infectious Diseases Pharmacist Recommendations: A 5-Year Outcome Study in a Multihospital System.
指南 / 共识 · Hosp Pharm · 2023-12-06
一句话结论多医院系统5年数据显示,感染病药师抗菌药物管理建议总体接受率92%,接受建议与抗菌药物使用量、住院时间和费用降低相关,且未增加死亡率或再入院。

该多中心回顾性队列研究比较了2015年10月至2020年12月5年间ICU与非ICU患者中感染病药师抗菌药物管理建议被接受与被拒绝的临床结局。采用粗化精确匹配(CEM)平衡组间协变量以控制混杂。结果显示建议总体接受率92%,接受建议与抗菌药物使用量显著降低相关,未对死亡率或再入院产生不良影响;非ICU接受建议者住院时间平均缩短1天,避免费用约7 631 400美元。非ICU接受建议者因频繁降阶梯至头孢曲松,高危艰难梭菌抗生素使用显著增加,但医院获得性艰难梭菌感染和30天内社区起病艰难梭菌感染率未恶化。

要点

  • 多医院系统5年间感染病药师抗菌药物管理建议总体接受率92%。
  • 接受建议与抗菌药物使用量显著降低相关,且未对死亡率或再入院产生不良影响。
  • 非ICU接受建议者住院时间平均缩短1天,避免费用约7 631 400美元。
  • 非ICU接受建议者高危艰难梭菌抗生素使用显著增加(因频繁降阶梯至头孢曲松),但HA-CDI和30天内CO-CDI率未恶化。

适用人群与场景

  • ICU与非ICU患者,来自多医院卫生系统,时间为2015年10月至2020年12月共5年。

研究设计与关键结果

  • 研究类型:多中心回顾性队列研究,比较ICU与非ICU患者中感染病药师抗菌药物管理建议被接受与被拒绝的临床结局。
  • 匹配方法:采用粗化精确匹配(CEM)作为非参数匹配方法平衡组间协变量并控制混杂。
  • 主要结局指标包括:每1000患者日抗菌药物使用天数(DOT/1000 PD)、每1000患者日抗菌药物剂量(doses/1000 PD)、住院时间(LOS)、院内死亡率、医院获得性艰难梭菌感染(HA-CDI)、30天内社区起病艰难梭菌感染(CO-CDI)及30天内再入院。
  • 建议总体接受率为92%。
  • 接受建议与抗菌药物使用量显著降低相关,且未对死亡率或再入院产生不良影响。
  • 非ICU接受建议者因频繁降阶梯至头孢曲松,高危艰难梭菌抗生素使用显著增加,但HA-CDI和30天内CO-CDI率未恶化。
  • 非ICU接受建议者住院时间平均缩短1天,避免费用约7 631 400美元。

证据类型、等级与局限

  • 证据类型:多中心回顾性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,与感染病药师合作优化抗菌药物管理可显著降低抗菌药物使用量、费用和住院时间,且不恶化患者结局。

指南或共识出处

  • 美国感染病学会抗菌药物管理项目指南(The Infectious Diseases Society of America Guidelines for Antimicrobial Stewardship Programs)强烈推荐前瞻性审核与反馈。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Background: Infectious diseases (ID) pharmacists are pivotal members of antimicrobial stewardship teams. Prospective audit and feedback is a strong recommendation by The Infectious Diseases Society of America Guidelines for Antimicrobial Stewardship Programs (ASP). Utilizing customized ASP intervention documentation tools known as "ivents" in Epic, we aimed to assess the impact of interventions by measuring outcomes that were accepted compared to those that were rejected in a multihospital health system over 5 years. Methods: A multicenter, retrospective cohort study was conducted to compare clinical outcomes among intensive care unit (ICU) and non-ICU patients with accepted and rejected ASP interventions over 5 years from October 2015 to December 2020. Outcomes measured included antibiotic days of therapy per 1000 patient days (DOT/1000 PD), antibiotic doses per 1000 patient days (doses/1000 PD), hospital length of stay (LOS), in-hospital mortality, hospital-acquired Clostridioides difficile infection (HA-CDI), community-onset C. difficile infection (CO-CDI) within 30 days, and hospital readmission within 30 days. Coarsened exact matching (CEM) was used as a non-parametric matching method to balance covariates between groups and to control for confounding. Results: ASP recommendations by ID pharmacists were well-received by providers in a multihospital system over 5 years as evidenced by an overall acceptance rate of 92%. Acceptance of ASP interventions was associated with substantial reductions in antibiotic utilization without adversely affecting mortality or hospital readmissions. While high-risk C. difficile antibiotic use increased significantly due to frequent de-escalation to ceftriaxone among non-ICU patients with accepted interventions, rates of HA-CDI and CO-CDI within 30 days did not worsen. Furthermore, hospital LOS was notably shorter by an average of 1 day for non-ICU patients with accepted interventions, which resulted in substantial cost avoidance of $7 631 400. Conclusion: Collaboration with ID pharmacists to optimize antimicrobial stewardship was associated with significant reductions in antibiotic utilization, costs, and hospital LOS without worsening patient outcomes.

来源:Hosp Pharm,查看原文。版权归原作者所有。

参考来源

  1. Babiarz T, Schmetterer J, Merrick K, et al. Benefits of Accepting Infectious Diseases Pharmacist Recommendations: A 5-Year Outcome Study in a Multihospital System. Hosp Pharm. 2023. PMID: 38765000. doi:10.1177/00185787231213807

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。